Form 4: Aldeyra Therapeutics Executive Sells Shares to Cover Tax Obligations

Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, sold 16,041 shares of common stock to cover tax withholding obligations.

Summary

• On August 12, 2024, Stephen Machatha, the Chief Development Officer of Aldeyra Therapeutics, sold 16,041 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations related to the settlement of time-based restricted stock unit awards.
• The shares were sold at a weighted average price of $4.7363, with individual transactions ranging from $4.46 to $5.12.
• Following the transaction, Machatha directly owns 236,771 shares of Aldeyra Therapeutics.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (sale of shares for tax obligations) by an executive, which is neither particularly positive nor negative. It's a neutral event in terms of investment sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, covering tax obligations, and doesn't necessarily indicate a change in Machatha's long-term outlook on the company.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price, but is unlikely to be significant given the reason for the sale.

Key Dates